Considering FOLFOXIRI plus bevacizumab for metastatic colorectal cancer with left-sided tumors

被引：0

作者：

Yu Sunakawa

Hironaga Satak

Wataru Ichikawa

机构：

[1] Department of Clinical Oncology,St. Marianna University School of Medicine,Kawasaki

[2] Cancer Treatment Center,Kansai Medical University Hospital

[3] Division of Medical Oncology,Showa University Fujigaoka Hospital

来源：

World Journal of Gastrointestinal Oncology | 2018年 / 12期

关键词：

Tumor sidedness; FOLFOXIRI; Bevacizumab; Colorectal cancer; RAS mutation;

D O I：

暂无

中图分类号：

R735.34 [];

学科分类号：

100214 ;

摘要：

A recent subgroup analysis of the TRIBE trial suggested that FOLFOXIRI plus bevacizumab may be a preferred option for the first-line treatment of only right-sided metastatic colorectal cancer(mCRC), regardless of RAS or BRAF status. Our subanalysis of a phase Ⅱ trial of the FOLFOXIRI triplet regimen plus bevacizumab in patients with mCRC who had RAS mutant tumors showed that tumor shrinkage was better and the duration of treatment was longer in patients with leftsided tumors than in those with right-sided tumors, leading to a higher rate of conversion to surgery in mCRC patients with left-sided tumors. The early and deep responses to the triplet-regimen in patients with left-sided tumors might facilitate conversion treatment resulting in favorable survival. Our data suggest that the FOLFOXIRI plus bevacizumab might be a promising treatment for left-sided mCRC involving RAS mutant tumors.

引用

页码：528 / 531

页数：4

共 6 条

[1]

A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11.[J] . Satake Hironaga,Sunakawa Yu,Miyamoto Yuji,Nakamura Masato,Nakayama Hiroshi,Shiozawa Manabu,Makiyama Akitaka,Kobayashi Kazuma,Kubota Yutaro,Mori Misuzu,Kotaka Masahito,Takagane Akinori,Gotoh Masahiro,Takeuchi Masahiro,Fujii Masashi,Ichikawa Wararu,Sekikawa Takashi. Oncotarget . 2018 (27)

[2]

Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS.[J] . Yoshino T,Arnold D,Taniguchi H,Pentheroudakis G,Yamazaki K,Xu R-H,Kim T W,Ismail F,Tan I B,Yeh K-H,Grothey A,Zhang S,Ahn J B,Mastura M Y,Chong D,Chen L-T,Kopetz S,Eguchi-Nakajima T,Ebi H,Ohtsu A,Cervantes A,Muro K,Tabernero J,Minami H,Ciardiello F,Douillard J-Y. Annals of oncology : official journal of the Europ

[3]

“CHARTA”: FOLFOX/Bevacizumab vs. FOLFOXIRI/Bevacizumab in advanced colorectal cancer—Final results, prognostic and potentially predictive factors from the randomized Phase II trial of the AIO.[J] . Schmoll Hans Joachim,Meinert Fabian Maximilian,Cygon Franziska,Garlipp Benjamin,Junghanss Christian,Leith?user Malte,Vogel Arndt,Schaefers Michael,Kaiser Ulrich,Hoeffkes Heinz Gert,Florschütz Axel,Rüssel J?rn,Kanzler Stephan,Edelmann Thomas,Forstbauer Helmut,Goehler Thomas,Hannig Carla,Hildebran

[4]

Updated efficacy, safety, and biomarker analyses of STEAM, a randomized, open-label, phase II trial of sequential (s) and concurrent (c) FOLFOXIRI-bevacizumab (BV) vs FOLFOX-BV for first-line (1L) treatment (tx) of patie[J] . Hurwitz Herbert,Tan Benjamin R.,Reeves James Andrew,Xiong Henry Q.,Somer Bradley G.,Lenz Heinz Josef,Hochster Howard S.,Scappaticci Frank,Palma John F.,Mancao Christoph,Lee John J.,Nicholas Alan,Sommer Nicolas,Bendell Johanna C.. Journal of Clinical Oncology . 201

[5]

Early tumor shrinkage and depth of response predict long-term outcome in metastatic colorectal cancer patients treated with first-line chemotherapy plus bevacizumab: results from phase III TRIBE trial by the Gruppo Oncol[J] . C. Cremolini,F. Loupakis,C. Antoniotti,S. Lonardi,G. Masi,L. Salvatore,E. Cortesi,G. Tomasello,R. Spadi,A. Zaniboni,G. Tonini,C. Barone,S. Vitello,R. Longarini,A. Bonetti,M. D’Amico,S. Di Donato,C. Granetto,L. Boni,A. Falcone. Annals of Oncology . 2015 (6)

[6]

Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer.[J] . Loupakis Fotios,Cremolini Chiara,Masi Gianluca,Lonardi Sara,Zagonel Vittorina,Salvatore Lisa,Cortesi Enrico,Tomasello Gianluca,Ronzoni Monica,Spadi Rosella,Zaniboni Alberto,Tonini Giuseppe,Buonadonna Angela,Amoroso Domenico,Chiara Silvana,Carlomagno Chiara,Boni Corrado,Allegrini Giacomo,Boni Luca,Falcone Alfredo. The New England journal of medicine . 2014 (17)

← 1 →